Crisaborole 2% ointment is a non-steroidal treatment for mild-moderate atopic dermatitis (AD) and may have a better safety profile than topical corticosteroids (TCS), which produce pronounced epidermal atrophy. In this study we compared crisaborole to betamethasone valerate (BMV) in terms of changes to dermal collagen, using PS-OCT to quantify dermal birefringence. 37 subjects were enrolled in this study, which involved daily application of BMV & crisaborole. Results showed BMV produced a significant increase in dermal birefringence, whereas crisaborole showed no significant change. PS-OCT may thus have an important role in the safety assessment of non-steroidal alternatives to TCS.
Access to the requested content is limited to institutions that have purchased or subscribe to SPIE eBooks.
You are receiving this notice because your organization may not have SPIE eBooks access.*
*Shibboleth/Open Athens users─please
sign in
to access your institution's subscriptions.
To obtain this item, you may purchase the complete book in print or electronic format on
SPIE.org.
INSTITUTIONAL Select your institution to access the SPIE Digital Library.
PERSONAL Sign in with your SPIE account to access your personal subscriptions or to use specific features such as save to my library, sign up for alerts, save searches, etc.